{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:46:23Z","timestamp":1648622783325},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1157\/13115028","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T21:50:44Z","timestamp":1208901044000},"page":"60-65","source":"Crossref","is-referenced-by-count":1,"title":["Quimioterapia intensiva y de rescate con progenitores hematopoy\u00e9ticos aut\u00f3logos en el tratamiento de los linfomas no hodgkinianos"],"prefix":"10.1016","volume":"130","author":[{"given":"Mariano","family":"Provencio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"E. Fayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13115028_bb0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/152581601750098453","article-title":"Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgki\u0144s lymphoma patients mobilized with different growth factors","volume":"10","author":"Gazitt","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1157\/13115028_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(04)01646-8","article-title":"B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma","volume":"5","author":"Jacobsen","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1157\/13115028_bb0015","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.1996.14.9.2454","article-title":"Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma: A case-matched comparison with unpurged cases by the European Blood Marrow Transplant Lymphoma Registry","volume":"14","author":"Willians","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1200\/JCO.1999.17.1.216","article-title":"Patterns of outcome following recurrece after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma","volume":"17","author":"Apostolidis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0030","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.bmt.1702660","article-title":"Autologous stem cell transplantation with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival","volume":"26","author":"Gonz\u00e1lez-Barca","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1157\/13115028_bb0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.bmt.1702336","article-title":"Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation","volume":"25","author":"Voso","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1157\/13115028_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bmt.1702631","article-title":"Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for folicullar lymphoma with high tumor burden: a GOELAMS phase II study","volume":"26","author":"Colombat","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1157\/13115028_bb0050","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prologs progresi\u00f3n-free survival innfollicular lymphoma-results of a prospective randomized trial of the german Low-grade Lymphoma Study Group (GLSG)","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0055","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients wih advanced follicular lymphoma: a randomised multicenter study by the GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0060","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0065","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1703829","article-title":"PCR detection of residual Bcl2\/IgH-positive cells after high-doses therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin\u2019s lymphoma","volume":"31","author":"Mahe","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1157\/13115028_bb0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1044-579X(03)00019-1","article-title":"The role of stem cell transplantation in the treatment of follicular lymphoma","volume":"13","author":"Finke","year":"2003","journal-title":"Sem Cancer Biol"},{"key":"10.1157\/13115028_bb0075","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/1042819031000067710","article-title":"CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin\u2019s lymphomas","volume":"44","author":"Pan","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1157\/13115028_bb0080","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.1992.10.6.942","article-title":"Survival after relapse of low-grade non-Hodgkin\u2019s lymphoma: Implications for bone marrow transplantation","volume":"10","author":"Weisdorf","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0085","first-page":"274a","article-title":"Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL)","volume":"106","author":"Fayad","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1157\/13115028_bb0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/annonc\/mdf119","article-title":"Survival after progression in follicular lymphomas: analysis of prognostic factors","volume":"13","author":"Montoto","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1157\/13115028_bb0095","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0100","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgki\u0144s lymphoma: results from the randomised Eurpean CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin\u2019s lymphoma","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1157\/13115028_bb0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is asociated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1157\/13115028_bb0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2004.05194.x","article-title":"Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantatio","volume":"127","author":"Toze","year":"2004","journal-title":"Br J Haem"},{"key":"10.1157\/13115028_bb0120","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated lowgrade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1157\/13115028_bb0125","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/bbmt.1999.v5.pm10465106","article-title":"Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies","volume":"5","author":"Friedberg","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1157\/13115028_bb0130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgki\u0144s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0135","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","article-title":"Autotransplants for histologically transformed follicular non-Hodgkin\u2019s lymphoma","volume":"113","author":"Chen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1157\/13115028_bb0140","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.1988.6.8.1303","article-title":"Autologous bone marrow transplantation for patients with poor-prognosis lymphoma","volume":"6","author":"Gulati","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0145","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.1996.14.2.586","article-title":"Survival benefif from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin\u2019s lymphoma","volume":"14","author":"Pettengell","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1008338607231","article-title":"Clinical outcome after autologous transplantation in non-Hodgki\u0144s lymphoma patients with high International Prognostic Index (IPI)","volume":"10","author":"Cortelazzo","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1157\/13115028_bb0155","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-hodgkin\u2019s lymphoma: final analysis of the prospective LNH 87-2 protocol-a Groupe d\u2019\u00c9tude des Lymphomes de l\u2019adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0160","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressve lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin\u2019s lymphoma: an Italian Multicentrer Randomized Trial","volume":"21","author":"Oyan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard chemotherapy with or without highdose chemotherapy for aggressive non-Hodgkin\u2019s lymphoma: randomised phase III study","volume":"93","author":"Kluin-Nelemans","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1157\/13115028_bb0175","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13115028_bb0180","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","volume":"16","author":"Santini","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0185","doi-asserted-by":"crossref","unstructured":"Milpied N, Deconinck E, Gaillard F, Delwail V, Foussaard C, Berthou C, et al. Initial treatment of aggressive lymphoma with High-dose chemotherapy and autologous stem-cell support. 2004;350:1287-95.","DOI":"10.1056\/NEJMoa031770"},{"key":"10.1157\/13115028_bb0190","first-page":"1304","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin\u2019s lymphoma: a meta-analysis","volume":"88","author":"Strehl","year":"2003","journal-title":"Haematologica"},{"key":"10.1157\/13115028_bb0195","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/annonc\/mdh353","article-title":"Log-term follow- up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index","volume":"15","author":"Bertz","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1157\/13115028_bb0200","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.2005.07.039","volume":"23","author":"Van Imhoff","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0205","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1200\/JCO.2002.07.075","article-title":"Randomized study to evaluate the use of high-dose therapy as part of primary treatment for \u00abaggressive\u00bb lymphoma","volume":"20","author":"Kaiser","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0210","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/annonc\/mdl153","article-title":"Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the International randomized phase III trail (MISTRAL)","volume":"17","author":"Betticher","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1157\/13115028_bb0215","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemothrapy and autologous bone marrow transplantation for patients with relapsed or refractory non-hodgkin\u2019s lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0220","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/annonc\/mdi248","article-title":"High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma: results of a multicenter phase II study","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1157\/13115028_bb0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hon.773","article-title":"Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin\u2019s lymphoma achieving complete response only after autologous stem cell transplantation","volume":"24","author":"Ferrara","year":"2006","journal-title":"Hematol Oncol"},{"key":"10.1157\/13115028_bb0230","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/10428190600570958","article-title":"High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed\/refractory lymphoma","volume":"47","author":"Oyan","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1157\/13115028_bb0235","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1157\/13115028_bb0240","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.1998.16.10.3264","article-title":"Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial","volume":"16","author":"Guglielmi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0245","first-page":"3562","article-title":"The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0250","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2003.09.015","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission","volume":"10","author":"Vose","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1157\/13115028_bb0255","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V73.7.1749.bloodjournal7371749","article-title":"Bone marrow transplantation in the treatment of patients with lymphoma","volume":"7","author":"Armitage","year":"1989","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0260","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1083-8791(00)70065-6","article-title":"Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory\/ recurrent non-Hodgkin\u2019s lymphoma","volume":"6","author":"Johnston","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1157\/13115028_bb0265","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantion for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0270","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2002-12-3842","article-title":"Prognostic value of pre-transplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation","volume":"102","author":"Spaepen","year":"2003","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0280","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F] fluoro-2-deoxy-D-glucose positron emission tomography in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0285","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13115028_bb0290","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2004-04-1532","article-title":"Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas","volume":"105","author":"Krishnan","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0295","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.exphem.2004.12.008","article-title":"HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation","volume":"33","author":"Serrano","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1157\/13115028_bb0300","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1157\/13115028_bb0305","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remission after treatment of newly diagnosed agressive mantle-cell lymphoma with rituximab plus high-dose metrotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0310","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0315","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.1157\/13115028_bb0320","doi-asserted-by":"crossref","first-page":"424s","DOI":"10.1200\/jco.2006.24.18_suppl.7511","article-title":"Mantle cell lymphoma (MCL): induction therapy with hyperCVAD\/high-dose methotrexate and cytarabine (M-C) (+\/-rituximab) improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0325","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0330","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1157\/13115028_bb0335","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":"Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed non-Hodgkin lymphoma","volume":"23","author":"Vose","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0340","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","article-title":"High dose rituximab before and after autologous stem cell transplantation for relapsing aggressive B-cell non-Hodgkin\u2019s lymphomas","volume":"23","author":"Khouri","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1157\/13115028_bb0345","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.blre.2004.11.003","article-title":"Microarray-based gene expresi\u00f3n profiling of hematologic malignancies: basic concepts and clinical applications","volume":"19","author":"Margalit","year":"2005","journal-title":"Blood reviews"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308713502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308713502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T17:22:59Z","timestamp":1588612979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775308713502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0025775308713502"],"URL":"https:\/\/doi.org\/10.1157\/13115028","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}